#Ireland #Dublin #Jazz Pharmaceuticals #Ziihera® #HER2+ GEA

Ziihera® Achieves Unprecedented Results in HER2+ Metastatic GEA Treatment

In a remarkable advancement for patients battling HER2-positive metastatic gastroesophageal adenocarcinoma (GEA), Ziihera® (zanidatamab-hrii) has demonstrated unprecedented efficacy and safety in recent clinical trials. The Phase 3 HERIZON-GEA-01 trial yielded results that are shifting the paradigm in treatment protocols for this aggressive cancer type.

Key Findings from the HERIZON-GEA-01 Trial

Conducted by Jazz Pharmaceuticals, the HERIZON-GEA-01 trial evaluated Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as a first-line treatment for adults with HER2-positive locally advanced or metastatic GEA. Notably, the trial has shown that:

1. Statistically Significant Progression-Free Survival (PFS)
- Patients treated with Ziihera plus chemotherapy showed a median PFS of 12.4 months, representing a significant 35% reduction in the risk of disease progression compared to the control arm receiving trastuzumab plus chemotherapy. This marks a critical improvement over prior treatment standards.

2. Extended Overall Survival (OS)
- Perhaps the most striking outcome was the median overall survival of more than two years (26.4 months) for the Ziihera plus tislelizumab and chemotherapy group, highlighting a remarkable improvement of over seven months compared to the control arm. This exceeds previous records for OS in Phase 3 trials focused on GEA.

3. Safety Profile
- The safety analysis revealed that the combinations of Ziihera with chemotherapy produced side effects that aligned with established HER2-targeted therapies, presenting a manageable profile for patients. The study noted that severe adverse effects were consistent and predictable, primarily involving gastrointestinal disturbances, notably diarrhea.

Expert Insights

Dr. Elena Elimova, a leading oncologist from the Princess Margaret Cancer Centre and one of the presenting authors, emphasized the significance of these results: “Reaching more than two years of median overall survival in a global Phase 3 trial for HER2+ metastatic GEA is truly unprecedented. The findings signal a meaningful step forward for patients who have historically faced limited long-term outcomes.”

Additionally, Dr. Geoffrey Ku from Memorial Sloan Kettering Cancer Center highlighted the broader implications: “These results are practice-changing… suggesting that zanidatamab plus chemotherapy, with or without tislelizumab, should become the new standard of care for patients with HER2+ GEA.”

Future Developments

As interest grows in these results, Jazz Pharmaceuticals is set to present further findings at the upcoming ASCO Gastrointestinal Cancers Symposium on January 8, 2026. The company is also progressing with regulatory submissions to seek approval for Ziihera as a standard treatment option in this patient population.

Moreover, Jazz is expanding its clinical trials to explore the efficacy of Ziihera across multiple HER2-expressing tumor types, including metastatic breast cancer, indicating a robust commitment to redefining treatment outcomes for various cancer patients.

A brighter future for HER2+ metastatic GEA patients now appears achievable with the success of Ziihera, demonstrating not only the efficacy of targeted therapies but also the potential for significantly improved survival rates in a traditionally hard-to-treat demographic. Beyond providing immediate therapeutic benefits, these findings herald a new era in cancer care that prioritizes longer-lasting remission and enhanced quality of life for patients around the world.